The stock of Legend Biotech Corp ADR (LEGN) has gone down by -2.58% for the week, with a 11.27% rise in the past month and a -18.48% drop in the past quarter. The volatility ratio for the week is 4.83%, and the volatility levels for the past 30 days are 5.96% for LEGN. The simple moving average for the past 20 days is 6.32% for LEGN’s stock, with a -19.71% simple moving average for the past 200 days.
Is It Worth Investing in Legend Biotech Corp ADR (NASDAQ: LEGN) Right Now?
The stock has a 36-month beta value of 0.17. Opinions on the stock are mixed, with 11 analysts rating it as a “buy,” 10 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for LEGN is 181.93M, and at present, short sellers hold a 7.20% of that float. On January 29, 2025, the average trading volume of LEGN was 1.48M shares.
LEGN) stock’s latest price update
Legend Biotech Corp ADR (NASDAQ: LEGN) has experienced a rise in its stock price by 1.29 compared to its previous closing price of 36.01. However, the company has seen a fall of -2.58% in its stock price over the last five trading days. seekingalpha.com reported 2025-01-07 that Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies, with a strong pipeline and global R&D presence. LEGN’s flagship product, CARVYKTI, has received multiple regulatory approvals and shows significant sales growth, with potential peak sales of at least $3B. The company has an impressive pipeline (with 11 non-CARVYKTI related programs), high growth rates, and strong liquidity stance with $1.2B in cash, ensuring funding into 2026, and low dilution risk.
Analysts’ Opinion of LEGN
Many brokerage firms have already submitted their reports for LEGN stocks, with Redburn Atlantic repeating the rating for LEGN by listing it as a “Buy.” The predicted price for LEGN in the upcoming period, according to Redburn Atlantic is $86 based on the research report published on October 08, 2024 of the previous year 2024.
Truist, on the other hand, stated in their research note that they expect to see LEGN reach a price target of $88. The rating they have provided for LEGN stocks is “Buy” according to the report published on June 17th, 2024.
H.C. Wainwright gave a rating of “Buy” to LEGN, setting the target price at $73 in the report published on May 24th of the previous year.
LEGN Trading at -0.44% from the 50-Day Moving Average
After a stumble in the market that brought LEGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.99% of loss for the given period.
Volatility was left at 5.96%, however, over the last 30 days, the volatility rate increased by 4.83%, as shares surge +12.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.47% lower at present.
During the last 5 trading sessions, LEGN fell by -2.75%, which changed the moving average for the period of 200-days by -33.81% in comparison to the 20-day moving average, which settled at $34.30. In addition, Legend Biotech Corp ADR saw 12.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LEGN starting from Macomber Lori, who proposed sale 2,254 shares at the price of $32.19 back on Jan 10 ’25. After this action, Macomber Lori now owns shares of Legend Biotech Corp ADR, valued at $72,553 using the latest closing price.
Huang Ying, the Officer of Legend Biotech Corp ADR, proposed sale 63,061 shares at $32.45 during a trade that took place back on Dec 24 ’24, which means that Huang Ying is holding shares at $2,046,512 based on the most recent closing price.
Stock Fundamentals for LEGN
Current profitability levels for the company are sitting at:
- -0.54 for the present operating margin
- 0.61 for the gross margin
The net margin for Legend Biotech Corp ADR stands at -0.67. The total capital return value is set at -0.19. Equity return is now at value -28.35, with -19.47 for asset returns.
Based on Legend Biotech Corp ADR (LEGN), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -0.45. The debt to equity ratio resting at 0.31. The interest coverage ratio of the stock is -12.59.
Currently, EBITDA for the company is -477.87 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 12.67. The receivables turnover for the company is 5.0for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.98.
Conclusion
To sum up, Legend Biotech Corp ADR (LEGN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
